false 0001633932 0001633932 2024-03-06 2024-03-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): March 6, 2024

 

 

 

ESSA Pharma Inc.

(Exact name of registrant as specified in its charter)

 

 

 

British Columbia, Canada

(State or other jurisdiction of incorporation)

001-37410

(Commission File Number)

98-1250703

(IRS Employer Identification No.)

     

Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada

(Address of principal executive offices)

V5Z 1K5

(Zip Code)

 

Registrant’s telephone number, including area code: (778) 331-0962

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)  		   Name of each exchange on which registered  
Common Shares, no par value   EPIX   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

The following information is filed pursuant to Item 5.07, “Submission of Matter to a Vote of Security Holders.”

 

On March 6, 2024, ESSA Pharma Inc. (the “Company”), held its 2024 annual general meeting of shareholders (the “Meeting”). A total of 33,428,657 of the Company’s common shares were present or represented by proxy at the meeting, representing approximately 75.69% of the Company’s 44,163,647 common shares that were outstanding and entitled to vote at the Meeting as of the record date of January 16, 2024. Set forth below are the matters acted upon by the Company’s shareholders at the Meeting, and the final voting results on each matter. Each of the proposals are described in further detail in the Company’s definitive proxy statement dated January 26, 2024, filed with the Securities and Exchange Commission on January 26, 2024.

 

Proposal 1: Setting the Number of Directors

 

For 33,424,783  
Against 3,874  
Abstain 0  
Broker Non-Votes 0  

 

Proposal 2: Election of Directors

 

Nominee  Votes For   % Votes For   Votes Withheld   % Votes Withheld   Broker Non-Votes 
David R. Parkinson   29,947,985    99.73%   81,989    0.27%   3,398,683 
Richard M. Glickman   29,948,035    99.73%   81,939    0.27%   3,398,683 
Gary Sollis   29,945,788    99.72%   84,186    0.28%   3,398,683 
Franklin M. Berger   29,937,249    99.69%   92,725    0.31%   3,398,683 
Scott Requadt   29,947,985    99.73%   81,989    0.27%   3,398,683 
Marella Thorell   23,840,414    79.39%   6,189,560    20.61%   3,398,683 
Alex Martin   30,014,431    99.95%   15,543    0.05%   3,398,683 
Sanford Zweifach   30,013,358    99.94%   16,616    0.06%   3,398,683 
Philip Kantoff   30,014,381    99.95%   15,593    0.05%   3,398,683 
Lauren Merendino   30,015,635    99.95%   14,339    0.05%   3,398,683 

 

Proposal 3: Appointment and Remuneration of Auditors

 

For 33,422,178  
Withheld 6,478  
Broker Non-Votes 1  

 

Proposal 4: Advisory Vote on the Compensation of the Company’s Named Executive Officers

 

For 29,699,866  
Against 330,108  
Abstain 0  
Broker Non-Votes 3,398,683  

 

Proposal 5: Approval of Omnibus Incentive Plan Amendment

 

For 29,566,002  
Against 463,972  
Abstain 0  
Broker Non-Votes 3,398,683  

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ESSA PHARMA INC.
  (Registrant)

 

Date: March 7, 2024

 

  By: /s/ David Wood
    Name:David Wood
    Title:Chief Financial Officer

 

 

v3.24.0.1
Cover
Mar. 06, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 06, 2024
Entity File Number 001-37410
Entity Registrant Name ESSA Pharma Inc.
Entity Central Index Key 0001633932
Entity Tax Identification Number 98-1250703
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 720
Entity Address, Address Line Two 999 West Broadway
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V5Z 1K5
City Area Code 778
Local Phone Number 331-0962
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol EPIX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
ESSA Pharma (NASDAQ:EPIX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos ESSA Pharma.
ESSA Pharma (NASDAQ:EPIX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos ESSA Pharma.